HMGB1 and cancer: Hubert et al. [82], reported pro-tumour/immuno-suppressive effect of HMGB1, and suppression of tumour development ensuing stimulation of adaptive immune responses via profound re-modification of immune micro-milieu by HMGB1 inhibition, thereby enhancing the efficacy of [anti-programmed cell death ligand 1 (PD-L1)] mono-immunotherapeutics in cancer.